SIEMENS

A Matter of Confidence.



Beyond Doubt.

Proven clinical outcomes and cost-effectiveness. Over 2 million clinical studies spanning 20 years of investigation in collaboration with leading medical institutions worldwide. More than 2500 scientific publications. Definitive clinical results.

Siemens Positron Imaging. Setting standards of excellence since 1976... with seven generations of advanced positron detection systems. Unsurpassed count rate performance and sensitivity. Validated attenuation techniques and quantitation. Practical whole body imaging protocols. Superb image quality.

A Matter of Confidence. There *is* a standard in positron imaging today. It's proven. It's the one you would use on your family or friends if they needed care. It's already in extensive clinical use around the world. And it's been defined by Siemens.

The Future in Positron Imaging. Positron imaging is rapidly evolving. That's why we are defining new standards. Ones that will make dedicated PET systems more powerful and affordable—and bring an unprecedented level of performance to a new class of PET/SPECT imagers.

Yes. It is a matter of confidence. Confidence in your choice of technology...in the long term value of your purchase. And in the commitment level of your partner...to bringing a proven standard of excellence to every positron imaging procedure and patient you serve.

And isn't that what *really* matters?

Siemens The Standard in Positron Imaging.

The PET/SPECT option is pending 510(k) review and is not yet commercially available in the U.S.





whole body positron image



whole body positron image

Siemens Medical Systems, Inc. • North and South America 847.304.7700 • Canada 905.819.8000 • Europe 49.9131.84.6685 • Asia and Pacific Rim 81.3.5423.4066
E-mail: feedback@po4.nmg.sms.siemens.com • Web site: http://www.sms.siemens.com/nmg

If nuclear medicine is constantly changing, shouldn't your thyroid uptake system be able to keep up?

Imagine buying a thyroid uptake system that's built to last...and to adapt.

The CAPTUS® 2000 offers the most advanced capabilities from subtracting a predose measurement, counting a single capsule and multiplying by the number given, to measuring residual liquid activity in a vial after the dose is given. Design innovations such as the spring arm stand and automated constancy tests make it easier and faster to use.



But the most powerful advantage of the CAPTUS® 2000 is in its Intel® Pentium® Processor and familiar Microsoft Windows® based software. As new procedures are developed, they can be programmed into the software with the insertion of a disk. Introducing a new technique doesn't require a new equipment purchase.

The CAPTUS® 2000: built for high performance today...and tomorrow.

CAPINTEC, INC.

6 Arrow Rd., Ramsey, N.J. USA 07446
Toll Free (800) 631-3826/(201) 825-9500
FAX (201) 825-4829, www:capintec.com

Xian Liya Electronic
Instruments Co,. Ltd.
No.11, East Xiao Zhai Road
Xian, Shaanxi Province
Peoples Republic of China

Circle Reader Service No. 23

It's better under stress

The value of cardiac imaging lies in the accuracy of stress perfusion images. And that's where Cardiolite® comes through.

With Cardiolite, you can simultaneously obtain stress perfusion and resting function *(gated stress Cardiolite study)*—that's critical diagnostic information regarding cardiac perfusion, wall motion, wall thickening, and LVEF—all of which can help with patient management decisions. And, for patients unable to achieve adequate levels of stress through exercise, imaging results can be optimized by using pharmacologic agents such as I.V. Persantine® (dipyridamole USP).

To enhance patient management, find out about the advantages of stress Cardiolite before you order your next study.



By performing stress Cardiolite studies you can...

- Accurately diagnose CAD
- Risk stratify patients with known or suspected CAD
- Reduce equivocal interpretation in difficult-to-image patients (women, obese, and large-chested)
- Acquire stress perfusion and resting function information
- Improve patient management decisions, which may reduce costs

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

To reduce the uncertainty Cardiolite comes through

DU PONT PHARMA
Radiopharmaceuticals

Stress testing should be performed only under the supervision of a qualified physician in a laboratory equipped with appropriate resuscitation and support apparatus. There have been infrequent reports of signs and symptoms consistent with seizure and severe hypersensitivity after administration of Tc99m Sestamibi. Pharmacologic stress may be associated with serious adverse events such as myocardial infarction, arrhythmias, hypertension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise.

Persantine® is a registered trademark of Boehringer Ingelheim International GmbH. *I.V. Persantine*® is manufactured and distributed by DuPont Pharma under license from Boehringer Ingelheim Pharmaceuticals, Inc.

Please see brief summary of prescribing information on adjacent page.

Brief Summary

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

FOR DIAGNOSTIC USE

INDICATIONS AND USAGE: CARDIOLITE®, Kit for the preparation of Technetium Tc99m Sestamibi, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling).

It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia.

CONTRAINDICATIONS: None known.

WARNINGS: In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See PRECAUTIONS).

Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmias, hypotension, bronchoconstriction and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling.

PRECAUTIONS:

GENERAL

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to the patients consistent with proper patient management.

Contents of the kit before preparation are not radioactive. However, after the Sodium Pertechnetate Tc99m Injection is added, adequate shielding of the final preparation must be maintained.

The components of the kit are sterile and non-pyrogenic. It is essential to follow directions carefully and to adhere to strict aseptic procedures during preparation.

Technetium Tc99m labeling reactions involved depend on maintaining the stannous ion in the reduced state. Hence, Sodium Pertechnetate Tc99m Injection containing oxidants should not be used.

Technetium Tc99m Sestamibi should not be used more than six hours after preparation.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation and support apparatus.

The most frequent exercise stress test endpoints, which resulted in termination of the test during controlled Tc99m Sestamibi studies (two-thirds were cardiac patients) were:

Fatigue	35%
Dyspnea	17%
Chest Pain	16%
ST-depression	7%
Arrhythmia	1%

Carcinogenesis, Mutagenesis, Impairment of Fertility

In comparison with most other diagnostic technetium labeled radiopharmaceuticals, the radiation dose to the ovaries (1.5rads/30mCi at rest, 1.2 rads/30mCi at exercise) is high. Minimal exposure (ALARA) is necessary in women of childbearing capability. (See Dosimetry subsection in DOSAGE AND ADMINISTRATION section.)

The active intermediate, $[Cu(MIBI)_4]BF_4$, was evaluated for genotoxic potential in a battery of five tests. No genotoxic activity was observed in the Ames, CHO/HPRT and sister chromatid exchange tests (all *in vitro*). At cytotoxic concentrations (≥ 20μg/ml), an increase in cells with chromosome aberrations was observed in the *in vitro* human lymphocyte assay. $[Cu(MIBI)_4]BF_4$ did not show genotoxic effects in the *in vivo* mouse micronucleus test at a dose which caused systemic and bone marrow toxicity (9mg/kg, > 600 × maximal human dose).

Pregnancy Category C

Animal reproduction and teratogenicity studies have not been conducted with Technetium Tc99m Sestamibi. It is also not known whether Technetium Tc99m Sestamibi can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There have been no studies in pregnant women. Technetium Tc99m Sestamibi should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Technetium Tc99m Pertechnetate is excreted in human milk during lactation. It is not known whether Technetium Tc99m Sestamibi is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS: During clinical trials, approximately 8% of patients experienced a transient parosmia and/or taste perversion (metallic or bitter taste) immediately after the injection of Technetium Tc99m Sestamibi. A few cases of transient headache, flushing, edema, injection site inflammation, dyspepsia, nausea, vomiting, pruritus, rash, urticaria, dry mouth, fever, dizziness, fatigue, dyspnea, and hypotension also have been attributed to administration of the agent. Cases of angina, chest pain, and death have occurred (see WARNINGS and PRECAUTIONS). The following adverse reactions have been rarely reported: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis in a wrist joint; and severe hypersensitivity, which was characterized by dyspnea, hypotension, bradycardia, asthenia and vomiting within two hours after a second injection of Technetium Tc99m Sestamibi.

DU PONT PHARMA
Radiopharmaceuticals

Marketed by
DuPont Radiopharmaceutical Division
The DuPont Merck Pharmaceutical Co.
331 Treble Cove Road
Billerica, Massachusetts, USA 01862
For ordering Tel. Toll Free: 800-225-1572
All other business: 800-362-2668
(For Massachusetts and International, call 508-667-9531)

513121-0296 2/96 Printed in U.S.A.

I.V. PERSANTINE®

(dipyridamole USP) Injection 5mg/ml

Brief Summary of Prescribing Information

INDICATIONS AND USAGE IV Persantine® (dipyridamole USP) is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately.

CONTRAINDICATIONS Hypersensitivity to dipyridamole.

WARNINGS Serious adverse reactions associated with the administration of intravenous Persantine® (dipyridamole USP) have included cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm. There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block. Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events.

In a study of 3911 patients given intravenous Persantine® as an adjunct to thallium myocardial perfusion imaging, two types of serious adverse events were reported: 1) four cases of myocardial infarction (0.1%), two fatal (0.05%), and two non-fatal (0.05%); and 2) six cases of severe bronchospasm (0.2%). Although the incidence of these serious adverse events was small (0.3%, 10 of 3911), the potential clinical information to be gained through use of intravenous Persantine® thallium imaging must be weighed against the risk to the patient. Patients with a history of unstable angina may be at a greater risk for severe myocardial ischemia. Patients with a history of asthma may be at a greater risk for bronchospasm during IV Persantine® use.

When thallium myocardial perfusion imaging is performed with intravenous Persantine®, parenteral aminophylline should be readily available for relieving adverse events such as bronchospasm or chest pain. Vital signs should be monitored during, and for 10-15 minutes following, the intravenous infusion of Persantine® and an electrocardiographic tracing should be obtained using at least one chest lead. Should severe chest pain or bronchospasm occur, parenteral aminophylline may be administered by slow intravenous injection (50-100 mg over 30-60 seconds) in doses ranging from 50 to 250 mg. In the case of severe hypotension, the patient should be placed in a supine position with the head tilted down if necessary, before administration of parenteral aminophylline. If 250 mg of aminophylline does not relieve chest pain symptoms within a few minutes, sublingual nitroglycerin may be administered. If chest pain continues despite use of aminophylline and nitroglycerin, the possibility of myocardial infarction should be considered. If the clinical condition of a patient with an adverse event permits a one minute delay in the administration of parenteral aminophylline, thallium-201 may be injected and allowed to circulate for one minute before the injection of aminophylline. This will allow initial thallium perfusion imaging to be performed before reversal of the pharmacologic effects of Persantine® on the coronary circulation.

PRECAUTIONS See WARNINGS

Drug Interactions Oral maintenance theophylline and other xanthine derivatives such as caffeine may abolish the coronary vasodilatation induced by intravenous Persantine® (dipyridamole USP) administration. This could lead to a false negative thallium imaging result (see Mechanism of Action).

Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole.

Carcinogenesis, Mutagenesis, Impairment of Fertility In studies in which dipyridamole was administered in the feed at doses of up to 75 mg/kg/day (9.4 times* the maximum recommended daily human oral dose) in mice (up to 128 weeks in males and up to 142 weeks in females) and rats (up to 111 weeks in males and females), there was no evidence of drug related carcinogenesis. Mutagenicity tests of dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (63 times* the maximum recommended daily human oral dose). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg/day.

*Calculation based on assumed body weight of 50 kg.

Pregnancy Category B Reproduction studies performed in mice and rats at daily oral doses of up to 125 mg/kg (15.6 times* the maximum recommended daily human oral dose) and in rabbits at daily oral doses of up to 20 mg/kg (2.5 times* the maximum recommended daily human oral dose) have revealed no evidence of impaired embryonic development due to dipyridamole. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, this drug should be used during pregnancy only if clearly needed.

*Calculation based on assumed body weight of 50 kg.

Nursing Mothers Dipyridamole is excreted in human milk.

Pediatric Use Safety and effectiveness in the pediatric population have not been established.

ADVERSE REACTIONS Adverse reaction information concerning intravenous Persantine® (dipyridamole USP) is derived from a study of 3911 patients in which intravenous Persantine® was used as an adjunct to thallium myocardial perfusion imaging and from spontaneous reports of adverse reactions and the published literature.

Serious adverse events (cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, asystole, sinus node arrest, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm.) are described above (see WARNINGS).

In the study of 3911 patients, the most frequent adverse reactions were: chest pain/angina pectoris (19.7%), electrocardiographic changes (most commonly ST-T changes) (15.9%), headache (12.2%), and dizziness (11.8%).

Drug-related adverse events occurring with >1% incidence in this study were: chest pain/angina pectoris (19.7%), headache (12.2%), dizziness (11.8%), electrocardiographic abnormalities/ST-T changes (7.5%), electrocardiographic abnormalities/extrasystoles (5.2%), hypotension (4.6%), nausea (4.6%), flushing (3.4%), electrocardiographic abnormalities/tachycardia (3.2%), dyspnea (2.6%), pain unspecified (2.6%), blood pressure lability (1.6%), hypertension (1.5%), paresthesia (1.3%), and fatigue (1.2%).

Less common adverse reactions occurring in 1% or less of the patients within the study included:

Cardiovascular System: Electrocardiographic abnormalities unspecified (0.8%), arrhythmia unspecified (0.6%), palpitation (0.3%), ventricular tachycardia (0.2% see WARNINGS), bradycardia (0.2%), myocardial infarction (0.1% see WARNINGS), AV block (0.1%), syncope (0.1%), orthostatic hypotension (0.1%), atrial fibrillation (0.1%), supraventricular tachycardia (0.1%), ventricular arrhythmia unspecified (0.03% see WARNINGS), heart block unspecified (0.03%), cardiomyopathy (0.03%), edema (0.03%).

Central and Peripheral Nervous System: Hypothesia (0.5%), hypertonia (0.3%), nervousness/anxiety (0.2%), tremor (0.1%), abnormal coordination (0.03%), somnolence (0.03%), dysphonia (0.03%), migraine (0.03%), vertigo (0.03%).

Gastrointestinal System: Dyspepsia (1.0%), dry mouth (0.8%), abdominal pain (0.7%), flatulence (0.6%), vomiting (0.4%), eructation (0.1%), dysphagia (0.03%), tenesmus (0.03%), appetite increased (0.03%).

Respiratory System: Pharyngitis (0.3%), bronchospasm (0.2% see WARNINGS), hyperventilation (0.1%), rhinitis (0.1%), coughing (0.03%), pleural pain (0.03%).

Other: Myalgia (0.9%), back pain (0.6%), injection site reaction unspecified (0.4%), diaphoresis (0.4%), asthenia (0.3%), malaise (0.3%), arthralgia (0.3%), injection site pain (0.1%), rigor (0.1%), earache (0.1%), tinnitus (0.1%), vision abnormalities unspecified (0.1%), dysgeusia (0.1%), thirst (0.03%), depersonalization (0.03%), eye pain (0.03%), renal pain (0.03%), perineal pain (0.03%), breast pain (0.03%), intermittent claudication (0.03%), leg cramping (0.03%). In additional postmarketing experience, there have been rare reports of allergic reaction including urticaria, pruritus, dermatitis and rash.

DU PONT PHARMA
Radiopharmaceuticals

Distributed by
Radiopharmaceutical Division
The DuPont Merck Pharmaceutical Co.
Billerica, MA 01862

2 ml ampule & 10 ml vial
Manufactured by
DuPont Merck Pharma
Manati, Puerto Rico 00674

10 ml ampule
Manufactured by
DuPont Merck Pharma
Aquadilla, Puerto Rico 00604

Boehringer Ingelheim

Licensed by
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877

Under license from
Boehringer Ingelheim
International GmbH

10 ml vial
Manufactured by
Ben Venue Laboratories, Inc.
Bedford, Ohio 44146

Printed in U.S.A. 4/95 513113-0495 Brief Summary

All solutions begin with a vision.



When it comes to accessing image data, nothing increases your field of vision like the new Dx Pinnacle.

With unmatched clinical processing, archiving flexibility and interdepartmental compatibility, the Dx Pinnacle is the most effective and powerful nuclear medicine software you can buy. The Dx Pinnacle open system architecture and expandable database lets you retrieve images from different modalities, providing instant access to high resolution images from anywhere in the hospital. Or anywhere in the world.

See us at SNM Booth #668. We'll open your eyes to the future of nuclear medicine.

MEDASYS

THE MEDICAL IMAGING COMPANY

815 NW 57TH AVE., SUITE 200
MIAMI, FL 33126
305-261-6025
FAX 305-261-9765

Circle Reader Service No. 123

THIS IS GOIN
EVERY

TRANSFORMING
technology
INTO knowledge

G TO CHANGE THING!

VT TECHNOLOGY

The next generation of nuclear imaging. Be there when we lift the wraps.
Society of Nuclear Medicine. June 2-5, 1997. Or contact us at 1-800-323-0550, e-mail us at info@nm.picker.com,
or visit our home page at http://www.picker.com/nuclear/nuclear.html.

PICKER

MORE THAN IMAGES. INSIGHT.



PET Image of
metastatic disease

Moderators:
Peter E. Valk, M.D. and
Michael E. Phelps, Ph.D.

INSTITUTE FOR
CLINICAL PET

Positron Imaging in Clinical Oncology

ICP/SNM Seminar

Tuesday, June 3, 1997 5:00-8:00 pm
Hilton Palacio del Rio
200 South Alamo Street
San Antonio, Texas

Course Outline

Imaging instrumentation, radiopharmaceutical delivery, clinical applications and reimbursement for positron imaging are rapidly changing. This course will provide an up-to-date perspective on the expansion of positron imaging technologies to include high energy collimation, dual head gamma cameras with coincidence detection, partial ring PET scanners and high end PET systems. The components of a radiopharmacy network that supplies FDG to clinics will be described. The clinical questions will be exemplified in the course by focusing on detection, staging and therapeutic assessment of various cancers with these positron imaging systems. Data from clinical trials, formulated into evidence based cost benefit analysis, will be presented along with an update on the status of reimbursement from various types of private and federal sources.

Program

5:00-5:05	Welcome	Peter E. Valk, M.D.
5:05-5:25	Positron Imaging Technology – Present and Future	Michael E. Phelps, Ph.D.
5:25-6:25	PET Imaging in Clinical Oncology	
	Solitary Pulmonary Nodules and Non-Small Cell Lung Cancer	R. Edward Coleman, M.D.
	Recurrent Colorectal Cancer	Peter E. Valk, M.D
	Metastatic Melanoma	Richard L. Wahl, M.D.
	Breast Cancer and Lymphoma	Carter S. Young, M.D.
	Head and Neck Cancer and Cancer of the Esophagus	Val J. Lowe, M.D.
6:25-6:40	BREAK	
6:40-7:10	Scintillation Camera FDG Imaging in Oncology	
	Cancer of the Lung and Colon	Martin P. Sandler, M.D.
	Cancer of the Lung, Esophagus and Head and Neck	Paul D. Shreve, M.D.
7:10-7:20	Availability and Delivery of FDG	Bradley W. Holmgren, R.Ph.
7:20-7:35	Cost Benefit Analysis for Oncological Positron Imaging	Sanjiv S. Gambhir, M.D., Ph.D.
7:35-7:45	Reimbursement for Oncological Positron Imaging	Ruth Dean Tesar, CNMT
7:45-8:00	Discussion	

You are not required to register to attend this seminar.
For further information, please contact the ICP office at 703-691-2255.

Amersham **HEALTHCARE**



Assisting Nuclear Medicine Improve Patient Management

Cardiology Products

MYOVIEW™
Technetium Tc99m Tetrofosmin for Injection

THALLIUM
Thallous Chloride-201

ADENOSCAN®
adenosine

HSA
Tc99m Albumin Injection

PYP
Tc99m Pyrophosphate

Services

Applications Assistance
1-800-323-0332

Medi-Physics Pharmacies
1-800-AHC-8004

Network Distribution

Customer Service
1-800-MEDI-123

Technical Service
1-800-TECH-MED

Adenoscan is a registered trademark of Fujisawa

See package inserts for full prescribing information

Brief Summary

MYOVIEW™

Kit for the Preparation of Technetium Tc99m Tetrofosmin for injection

Diagnostic radiopharmaceutical For intravenous use only
Code N166A

DESCRIPTION

The Medi-Physics Myoview™ kit is supplied as a pack of five vials for use in the preparation of a technetium Tc99m tetrofosmin intravenous injection to be used for the scintigraphic delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium. Each vial contains a pre-dispensed, sterile, non-pyrogenic, lyophilized mixture of 0.23 mg tetrofosmin [6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphospha-tetradecane], 30 µg stannous chloride dihydrate (minimum stannous tin 5.0 µg; maximum total stannous and stannic tin 15.8 µg), 0.32 mg disodium sulphosalicylate and 1.0 mg sodium D-gluconate, and 1.8 mg sodium hydrogen carbonate. The lyophilized powder is sealed under a nitrogen atmosphere with a rubber closure. The product contains no antimicrobial preservative.

Caution: Federal (USA) law prohibits dispensing without a prescription

CLINICAL PHARMACOLOGY

General
When technetium Tc99m pertechnetate is added to tetrofosmin in the presence of stannous reductant, a lipophilic, cationic technetium Tc99m complex is formed, Tc99m tetrofosmin. This complex is the active ingredient in the reconstituted drug product, on whose biodistribution and pharmacokinetic properties the indications for use depend.

Clinical Trials
A total of 252 patients with ischemic heart disease or atypical chest pain who had a reason for exercise stress imaging were studied in two open-label, multi center, clinical trials of Tc99m tetrofosmin (study a and study b). Of these 252 patients there were 212 (83%) males and 40 (17%) females with a mean age of 60.5 years (range 33.7 to 82.4 years). At peak exercise, maximum heart rate achieved and peak systolic blood pressure were comparable after Myoview and thallium-201 exercise studies.

All patients had exercise and rest planar imaging with Myoview and thallium-201; 191 (76%) patients also had SPECT imaging. The Myoview and thallium-201 images were separated by a mean of 5.1 days (1-14 days before or 2-14 days after Myoview). For Myoview imaging, each patient received 185-296 MBq (5-8 mCi) Tc99m tetrofosmin at peak exercise and 555-888 MBq (15-24 mCi) Tc99m tetrofosmin at rest approximately 4 hours later. For thallium-201 imaging, patients received thallium-201 55.5-74 MBq (1.5-2.0 mCi) at peak exercise.

The images were evaluated for the quality of the image (excellent, good or poor) and the diagnosis (with scores of 0 = normal, 1 = ischemia, 2 = infarct, 3 = mixed infarct and ischemia). The primary outcome variable was the percentage of correct diagnoses in comparison to the final clinical diagnosis. All planar images were blindly read; SPECT images were evaluated by the unblinded investigator. A subset of 181/252 (71%) patients had coronary angiography comparisons to the planar images of Myoview or thallium-201.

INDICATIONS AND USAGE

Myoview is indicated for scintigraphic imaging of the myocardium following separate administrations under exercise and resting conditions. It is useful in the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium.

CONTRAINDICATIONS

None known.

WARNINGS

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment.

PRECAUTIONS

General
To minimize radiation dose to the bladder, the patient should be encouraged to void when the examination is completed and as often thereafter as possible. Adequate hydration should be encouraged to permit frequent voiding.

The contents of the Myoview vial are intended only for use in the preparation of technetium

Tc99m tetrofosmin injection and are NOT to be administered directly to the patient.

As with all injectable drug products, allergic reactions and anaphylaxis may occur.

Sometimes Tc99m labeled myocardial imaging agents may produce planar and SPECT images with different imaging information.

Technetium Tc99m tetrofosmin injection, like other radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient management.

Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

Drug Interactions: Drug interactions were not noted and were not studied in clinical studies in which Myoview was administered to patients receiving concomitant medication. Drugs such as beta blockers, calcium blockers and nitrates may influence myocardial function and blood flow. The effects of such drugs on imaging results are not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies have not been conducted to evaluate carcinogenic potential or effects on fertility. Tetrofosmin sulphosalicylate was not mutagenic *in vitro* in the Ames test, mouse lymphoma, or human lymphocyte tests, nor was it clastogenic *in vivo* in the mouse micronucleus test.

Pregnancy Category C
Animal reproduction studies have not been conducted with Myoview. It is not known whether Myoview can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Therefore, Myoview should not be administered to a pregnant woman unless the potential benefit justifies the potential risk to the fetus.

Nursing Mothers
Technetium Tc99m Pertechnetate can be excreted in human milk. Therefore, formula should be substituted for breast milk until the technetium has cleared from the body of the nursing woman.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Adverse events were evaluated in clinical trials of 764 adults (511 men and 253 women) with a mean age of 58.7 years (range 26-94 years). The subjects received a mean dose of 7.67 mCi on the first injection and 22.4 mCi on the second injection of Myoview.

Deaths did not occur during the clinical study period of 2 days. Six cardiac deaths occurred 3 days to 6 months after injection and were thought to be related to the underlying disease or cardiac surgery. After Myoview injection, serious episodes of angina occurred in 3 patients. Overall cardiac adverse events occurred in 5/764 (less than 1 %) of patients after Myoview injection.

The following events were noted in less than 1 % of patients:
Cardiovascular: angina, hypertension, Torsades de Pointes
Gastrointestinal: vomiting, abdominal discomfort
Hypersensitivity: cutaneous allergy, hypotension, dyspnea
Special Senses: metallic taste, burning of the mouth, smelling something

There was a low incidence (less than 4%) of a transient and clinically insignificant rise in white blood cell counts following administration of the agent.

DOSAGE AND ADMINISTRATION

For exercise and rest imaging, Myoview is administered in two doses:

- The first dose of 5-8 mCi (185-296 MBq) is given at peak exercise.
- The second dose of 15-24 mCi (555-888 MBq) is given approximately 4 hours later, at rest.

Imaging may begin 15 minutes following administration of the agent.

Dose adjustment has not been established in renally or liver impaired, pediatric or geriatric patients.

RADIATION DOSIMETRY

Based on human data, the absorbed radiation doses to an average human adult (70 kg) from intravenous injections of the agent under exercise and resting conditions are listed in Table 1. The values are listed in descending order as rad/mCi and µGy/MBq and assume urinary bladder emptying at 3.5 hours.

Table 1
Estimated Absorted Radiation Dose (Technetium Tc99m Tetrofosmin Injection)

	Absorbed radiation dose			
	Exercise		Rest	
Target Organ	rad/mCi	µGy/MBq	rad/mCi	µGy/MBq
Gall bladder wall	0.123	33.2	0.180	48.6
Upper large intestine	0.075	20.1	0.113	30.4
Bladder wall	0.058	15.6	0.071	19.3
Lower large intestine	0.057	15.3	0.082	22.2
Small intestine	0.045	12.1	0.063	17.0
Kidney	0.039	10.4	0.046	12.5
Salivary glands	0.030	8.04	0.043	11.6
Ovaries	0.029	7.88	0.035	9.55
Uterus	0.027	7.34	0.031	8.36
Bone surface	0.023	6.23	0.021	5.58
Pancreas	0.019	5.00	0.018	4.98
Stomach	0.017	4.60	0.017	4.63
Thyroid	0.016	4.34	0.022	5.83
Adrenals	0.016	4.32	0.015	4.11
Heart wall	0.015	4.14	0.015	3.93
Red marrow	0.015	4.14	0.015	3.97
Spleen	0.015	4.12	0.014	3.82
Muscle	0.013	3.52	0.012	3.32
Testes	0.013	3.41	0.011	3.05
Liver	0.012	3.22	0.015	4.15
Thymus	0.012	3.11	0.009	2.54
Brain	0.010	2.72	0.008	2.15
Lungs	0.008	2.27	0.008	2.08
Skin	0.008	2.22	0.007	1.91
Breasts	0.008	2.22	0.007	1.83

Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev). Society of Nuclear Medicine, 1976. Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4), 1988) and gave values of 8.61×10^{-3} mSv/MBq and 1.12×10^{-2} mSv/MBq after exercise and rest respectively.

Manufactured by Amersham International plc – Amersham, United Kingdom
Patent No. 5,045,302 (r)

Distributed by: Medi-Physics, Inc., Amersham Healthcare
2636 S. Clearbrook Dr., Arlington Heights, IL 60005
1-800- 633-4123 (Toll Free)
February, 1996

Amersham HEALTHCARE

Curriculum Guide for Nuclear Medicine Technologists, 2nd Ed.

Wanda M. Mundy, EdD, CNMT, Gregory Passmore, MS, CNMT



A definitive educational reference tool for administrators and educators...

An essential in every professional's continuing education library.

Thoroughly revised in response to the latest advances in nuclear medicine technology, this new edition of the *Curriculum Guide* covers all key educational program areas.

- **Radiation Protection and Radiopharmacy Instrumentation**
- **Diagnostic Imaging and Patient Parameters**
- **Nonimaging Procedures**
- **Clinical Education**

Coverage targets curricula of hospital-based certificate programs with a structure aimed at national examinations. Curriculum can be easily supplemented for associate and baccalaureate degree programs.

APEX XPert

the integrated family

NEW

MagiCam*



Compact dual-head,all-purpose, variable-angle all-digital camera

Helix



Dual-head multi-purpose, Slip-Ring integrated digital gamma camera

CardiaL



Bi-plane right-angle, cardiac-all-purpose integrated digital camera

SPX-6

Integrated digital extra-large rectangular gamma camera

SPX-4

Integrated digital circular LFOV gamma camera

VariCam



NEW

Volumetric Coincidence Detection

Collimated Dual Isotope 140/511 keV

Premium dual-head, all-purpose, variable-angle, Slip-Ring all-digital gamma camera, featuring

Evolving Positron Imaging

TCP / IP DICOM 3.0

NEW

XPertPro



Advanced multi-task NM processing workstation

XPertView/L



Advanced NM viewing and teleradiology station

*W.I.P.

Elscint

The Intelligent Image

Elscint Asia-Pacific: Hong-Kong (2) 529-2231; Elscint Belgium: (2) 720-9246; Elscint Brazil: (11) 3766-2351; Elscint Canada: (905) 474-1229; Elscint Central & Eastern Europe: Austria (1) 985-5681; Elscint France: (14) 857-0818; Elscint Germany: (61) 227070; Elscint Middle East Operation: Israel (9) 7482-464; Elscint Italy: (2) 3932-0603; Elscint Mexico: (5) 254-5939; Elscint South Africa: (11) 482-3000; Elscint Spain: (3) 209-2199; Elscint U.K.: (1923) 239-511; Elscint U.S.A. (201) 342-2020; 1-800-ELSCINT. Internet website: http://www.elscint.co.il

Celebrate Nuclear Medicine Week

October 5 - 11, 1997

...by spotlighting your facility and demonstrating your enthusiasm, devotion and pride in your profession.

Nuclear Medicine Week gives you the opportunity to educate potential patients, referring physicians and your community about the history, value and safety of nuclear medicine.

Nuclear Medicine Week is sponsored by the Society of Nuclear Medicine and the Technologist Section.



Keep the celebration alive all year long!

Promoting your profession does not need to be limited to Nuclear Medicine Week. Take advantage of every opportunity throughout the year to increase the understanding and utilization of Nuclear Medicine.

Don't forget the annual PR Stars Contest! Be a Public Relations star and win prizes for yourself and your institution. Look for details and entry forms in JNM and JNMT.

This year's Nuclear Medicine Week merchandise entitled,

"Nuclear Medicine: For The Whole Picture"

was designed by the Technologist Section and will add to your festivities and enhance the visibility of nuclear medcine.

Poster: This eye-catching full-color illustrated poster chronicles a patient through a nuclear medicine procedure. Display the poster prominently, use it as a teaching tool or give it to referring physicians to promote nuclear medicine. **$5.00 each.**

Party Pack for 10 people: Open-houses are popular events designed to educate and encourage understanding. Add to your festivities by serving your guests treats on plates, cups and napkins adorned with the Nuclear Medicine Week message. **$10.00 for supplies for 10 people.**

Balloons: Put the celebration back in Nuclear Medicine Week by decorating your facility with these colorful balloons. Perfect for open-houses, job fairs or any activity throughout the year. **$1.00 for 4.**

Buttons & Stickers: Get the nuclear medicine message out by wearing the buttons and using the stickers on all your correspondence. A perfect, inexpensive give-away.
Buttons are $1.00 each.
Stickers are $1.00 for 4.

Candy Bag: Display these tasty peppermints for all to enjoy. Individually wrapped with the Nuclear Medicine Week message, these mints are a perfect give-away to your patients, referring physicians or at open-houses.
$5.00 for a bag of 50.

ORDER FORM ON THE FOLLOWING PAGE! ORDER NOW!!

THESE ITEMS ARE AVAILABLE FOR YOUR CELEBRATIONS YEAR-ROUND!

CELEBRATE NUCLEAR MEDICINE WEEK!

Fax: Credit Card Orders

913-362-7401

Faxed orders are accepted if submitted using this order form, includes payment by Visa or Mastercard, the complete credit card number, expiration date, cardholder's name as it appears on the card and signature.

Mail: Check & Credit Card Orders

Society of Nuclear Medicine
c/o MidPoint National
P.O. Box 411037
Kansas City, MO 64141-1037

Mail this order form along with your check or credit card information. Checks must be made payable in US dollars and drawn on US banks. No foreign funds accepted. Visa and Mastercard orders must include the credit card number, expiration date, cardholder's name as it appears on the card and signature.

Item	Quantity	Price	Total
Poster		$5.00 each	
Button		$1.00 each	
Stickers		$1.00 for 4	
Balloons		$1.00 for 4	
Candy Bag (approx. 50 pieces)		$5.00 per bag	
Party Pack (plates, napkins, cups) for 10		$10.00	
Guidelines: For Promoting Nuclear Medicine		FREE	FREE

Merchandise Total	$
Tax: In Virginia - 4.5%. In Kansas - 6.9%.	$
Shipping: (please allow 2-4 weeks for delivery) **If your merchandise total is:** $10.00 or less add: $3.00 $10.01 - $20.00 add: $5.00 $20.01 - $30.00 add: $7.00 $30.00 or more add: $10.00	$
Express Delivery & Foreign Orders: $25.00 Delivery Time: 1-2 Days. Express charge in addition to the regular shipping price.	$
Total Amount Due	$

Payment Method:

____ Check
Payable to: Society of Nuclear Medicine
____ VISA ____ Mastercard
____/____ Exp. Date

_____
Complete Credit Card Number

_____
Name as it appears on the Credit Card

_____
Cardholder's Signature

Shipping Information: please print clearly

Name:_____
Institution:_____
Address:_____
_____
City:_____
State:_____Zip:_____
Country:_____
Phone:(_____)_____

Express Delivery can not be shipped to a P.O. Box.

Purchase

all of the submitted handouts from the recent SNM Annual Meeting in San Antonio!

Two publications were prepared for the 44th Annual Meeting. First, the *Continuing Education Course Handout Materials* book contains all of the materials submitted to the Society by Continuing Education Course speakers. A bound book, this is a "must have" for all libraries!

The second book contains handouts from speakers for most of the *Sunday Categorical Seminar Courses*. This book will serve as another ready reference for all Nuclear Medicine libraries - at a bargain price!

If you are paying by credit card, fax your order form to 703•709•9274 today!

Please check one of the three boxes below:

☐ YES! Rush me both the *Continuing Education Course Handout Materials* book and the *Categorical Course Handout Materials* book! I understand that the cost per book is $25 and there is a $5 shipping and handling charge per book for US orders and $25 shipping and handling charge for foreign orders (all US orders will be mailed UPS). The total for both books is $60 for US and $75 for foreign.

☐ I'd like JUST the *Continuing Education Course Handout Materials* book ($25, plus $5 shipping and handling for US orders and $25 for overseas).

☐ I'd like JUST the *Categorical Course Handout Materials* book($25 plus $5 shipping and handling for US orders and $25 for overseas).

TOTAL ORDERED:_____

Questions? Call our Department: Meeting Services at 703•708•9000 x-229. Don't forget to visit us on the Internet! http://www.snm.org

PLEASE PRINT ALL FOLLOWING INFORMATION !!!

Please charge my ☐ VISA or ☐ MasterCard

Card Number:_____

Expiration date:_____

Signature:_____

☐ My check made out for the exact amount to the SNM is enclosed (mail original form to SNM, 1850 Samuel Morse Drive, Reston, VA 20190)

Shipping information (no P.O. boxes)

Ship my order to:_____

_____

Phone number:_____

Fax number:_____

Nuclear Medicine Positioning Products and Accessories

COMFORTABLE PATIENTS, QUALITY IMAGES!



Patient Support System I • Part #NMC201U



Patient Arm Support System II • Part #NMC700



Contoured Leg Rest 7" • Part #NMC807



Side Arm Holders • Part #NMC3017

Patient Arm Support System I & II

▶ ***Technologist inspired, patient tested***

passively supports patient's arms
engineered with flexibility to fit most imaging tables
comfortable patients require less assistance
fewer repeated and reprocessed studies

System I *Recommended for single and dual head imaging systems*
System II *Recommended for triple head imaging systems*

Side Arm Holders

▶ ***Improves productivity***

comfortable "at the side" arm positioning
universal design allows use on any imaging system
easy to use

Contoured Leg Rest

Enhance patient comfort ◀

comfortably supports patient's legs
reduce lower back stress and fatigue
quick and easy positioning
unique ergonomic design

Available in:
5", 7" and 10" Heights
compatible with all imaging systems

Nuclear Imaging Kit

Our most popular products ◀

Combines your choice of:
Patient Arm Support System I or II
7" Contoured Leg Rest
Side Arm Holders
in one convenient package

Call today for complete details or a catalog of our entire product line

PTI

PINESTAR
Technology, Inc.

P.O. Box 824, Greenville, PA 16125

Your complete source for Nuclear Medicine Supplies and Accessories.

Toll Free:	**800-682-2226**
Phone:	**412-932-2121**
Fax:	**412-932-3176**
Email:	**pti@nauticom.net**

Circle Reader Service No. 169



Boost Your Performance...

... on national certification examinations, with two new exam preparation texts from the Society of Nuclear Medicine Technologist Section—

The brand-new, illustrated *Preparation for Certification Examinations in Nuclear Medicine Technology* contains hundreds of self-quizzing questions and answers to help you perform at your peak. Mirroring the structure of those on national certification exams, these multiple-choice questions cover–

Radiopharmacy • Radiation Safety • Instrumentation • Patient Care • Clinical Procedures

Each answer is accompanied with thorough, easy-to-understand explanations and source references for more information.

And if your library doesn't include the recently updated *The Review of Nuclear Medicine Technology*, you're missing the single most effective exam study text you can own. New material includes the latest information on NRC regulations, recently introduced radiopharmaceuticals, and an expanded section on the rapidly growing field of nuclear cardiology.

Purchase *Preparation for Certification Examinations in Nuclear Medicine Technology* between now and August 1, 1997, and take advantage of the low introductory price of $20. And if you buy BOTH "Preparation" and the "Review," you'll save 10% of the combined cost of both books.

It's easy to order. Simply call the SNM's distributor, Matthews Medical Books, at their toll-free number–

1-800-633-2665 (non-U.S. 314-432-1401, or Fax: 314-432-7044).

SCOTT & WHITE

TEMPLE, TEXAS

Scott & White, one of the nation's largest medical centers, including a 464 physician clinic with 17 locations, a top rated 130,000 member HMO and a 486 bed teaching hospital affiliated with Texas A&M University Health Science Center College of Medicine located in Central Texas is actively recruiting for a **Nuclear Medicine Technologist**. Candidates must have ARRT(N) or NMTCB certification/registration as Nuclear Medicine Technologist and current Texas certification as a Radiology Tech.

Scott & White offers an excellent benefit package which includes: competitive salaries, relocation assistance, health, life, and disability insurance, and PTO. For more information please contact: ***Human Resources, 2401 S. 31st Street, Temple, Texas 76508; (800)527-JOBS or (817)724-2527. Fax 817-724-1631; http://www.sw.org. EOE.***

Position Available

Administrative Director

The University of Southern California is seeking an experienced manager for operations of its freestanding PET center and radiology research program. Applicants should have direct experience with billing/reimbursement, proven management skills, an understanding of research and grantsmanship, as well as knowledge of budgeting/financial planning in a cash-flow based environment. PET experience is a plus. USC offers excellent benefits and competitive salary. The environment is fast-paced, necessitating a dedicated individual with motivation and abilities to advance the success of operations. Mail or fax resume to: J. Keppler, 1510 San Pable, #350, Los Angeles, CA 90033. Fax: 213-342-5778.

Nuclear Medicine Physicist

Nuclear Medicine Service of San Diego Department of Veterans Affairs is recruiting a full-time nuclear medicine physicist. PhD in medical physics, biomedical engineering or related field is preferred. Expertise in Positron Emission Tomography (PET), two (2) years of experience in nuclear medicine and certification by the American Board of Nuclear Medicine Science (ABSNM) is preferred. Active clinical, teaching, research and administrative duties. Faculty appointment at the Department of Radiology of UCSD is available. Must be U.S. citizen. Apply by June 15, 1997 to: Director of Human Resources Management, San Diego VA Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161. EOE.

Nuclear Medicine Technologist

Nuclear Medicine Service of San Diego Department of Veterans Affairs is recruiting a full-time nuclear medicine technologist. CNMT certification and previous training/experience in Positron Emission Tomography (PET) is preferred. Must be U.S. citizen. Apply by June 15, 1997 to: Director of Human Resources Management, San Diego VA Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161. EOE

Medical Physicist/Imaging Scientist

The National Institutes of Health, Clinical Center in Bethesda,Maryland is seeking a full-time employee to become a member of the research team in cardiac and oncologic imaging. This research employs primarily nuclear medicine techniques (PET and SPECT), but also incorporates information from CT and MRI.

Applicants must possess a degree in physics or a related degree with at least 24 semester hours in physics. Applicants must be familiar with the physics problems associated with PET and/or SPECT imaging, the techniques of image processing and analysis and have some familiarity with the mathematical models used for quantitation in nuclear imaging (e.g., blood flow and glucose metabolism), and be interested in applying this knowledge to perform clinically relevant research. Experience in SPECT or PET imaging is required, preferably as applied to cardiac imaging. Familiarity with MRI/CT imaging a plus. Applicants should be knowledgeable about all aspects of research, from acquisition of clinical data to analysis and interpretation of clinical results. Strong computer skills are desirable.

Appointment is for two years with a maximum two-year extension possible. Annual salary (GS-13) ranges from $54,629 - $71,017, commensurate with qualifications. A complete federal benefits package is included. U.S. citizenship is required.

For further information about duties of this position, contact: Stephen Bacharach, PhD, National Institutes of Health, CC/NMD, Bldg. 10, Room 1C401, 10 Center Drive, MSC 1108, Bethesda, MD 20892-1108. Email: steve_bacharach@nih.gov.

For information on how to apply for this position, contact: Nicki Moses, National Institutes of Health, CC/OHRM/POS, 6100 Executive Blvd., Room 3E01, MSC 7509, Bethesda, MD 20892-7509. Phone: 301-496-6924.

NIH is an equal opportunity employer.

EXCELERATE℠



ZERO TO 64
SPECT slices processed
IN UNDER 5 SECONDS

CRUISE CONTROL
with automatic processing

HIGH PERFORMANCE
digital detectors

SPACIOUS INTERIOR
with unique open gantry

POPULAR OPTIONS PACKAGES like transmission attenuation correction (TAC™), auto-body contour (Trace™) and coincidence detection*

EXCELERATE℠ your nuclear medicine program with the Vision® DST·XL variable angle camera and POWERstation. To find out more about moving into the fast lane with SMV, please contact:

SMV America, Twinsburg, Ohio 1-800-664-0844
SMV International, Buc, France (33-1) 30-84-91-00

SMV

* Pending 510(k) clearance

Circle Reader Service No. 187

Can you benefit from nuclear imaging that delivers productivity at every possible angle?

Yes, you can.



TOSHIBA E.CAM™

Nuclear imaging without limits – this is the new reality with the combination of the versatile Toshiba E.CAM™ gammacamera and the powerful 64-bit UltraSPARC™ computer. Every nuclear procedure is now within your reach. Dual detector, variable-angle technology offers optimized imaging capabilities at any energy...and that means increased clinical utility and improved profitability. Combine the new standard in camera technology with the industry's fastest computing platform, and you can watch productivity race to a new level. The UltraSPARC Toshiba E.CAM system is a resounding illustration of Toshiba's commitment to nuclear imaging.

For more information about our *Yes, You Can* approach, call 1-800-521-1968.

In Touch with Tomorrow

TOSHIBA

http://www.toshiba.com

Circle Reader Service No. 192